News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Antyra Enters into Licensing Agreement for Anticancer Agents From Novo Nordisk A/S (NVO)


11/12/2008 9:58:18 AM

EDISON, N.J.--(BUSINESS WIRE)--Antyra, Inc. today announced that it has entered into a global licensing agreement with Novo Nordisk A/S (NYSE: NVO), for IGF-related antagonists for the treatment of cancer and other diseases. Under the Agreement, ANTYRA will obtain exclusive rights to develop and commercialize certain IGF antagonists discovered during the Research and License Collaboration Agreement entered into between the Companies in December 2001.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES